Kidney Blood Flow During Open Aortic Surgery (RENAL-SHUNT) (RENAL-SHUNT)

November 15, 2026 updated by: Rodolfo Pini, University of Bologna

Prospective Observational Evaluation of Temporary Selective Renal Blood Perfusion During Open Aortic Surgery With Suprarenal Cross-Clamping

During some operations on the abdominal aorta, the surgeon needs to temporarily clamp the aorta above the arteries that supply the kidneys. This can reduce blood flow to the kidneys and may cause acute kidney injury.

This study will follow 50 adults at Policlinico di Sant'Orsola in Bologna, Italy. During their operation, a temporary shunt will perfuse blood from humeral artery to the renal arteries. The treating surgeon decides whether to use the shunt as part of clinical care, independently of study participation.

The researchers will record how often kidney injury occurs in the first 7 days after surgery and how often problems related to the shunt, kidney arteries or arm access occur within 30 days. They will also track the need for dialysis, kidney function and survival over 12 months.

Study Overview

Status

Not yet recruiting

Intervention / Treatment

Detailed Description

RENAL-SHUNT is a single-center prospective observational registry of adults undergoing open abdominal aortic reconstruction requiring suprarenal or supravisceral cross-clamping. The surgical team may select passive renal blood perfusion when it anticipates prolonged or uncertain renal ischemia or considers the patient at high renal risk. The study observes a single exposed cohort. Treatment decisions are made independently of enrollment.

The registry will record baseline kidney function and preoperative acute kidney injury, aortic pathology, urgency, clamp level, periods of renal ischemia and perfusion, hemodynamics, transfusion and complications. Serum creatinine will be collected from routine postoperative assessments where available. Recorded urine output will be used for Kidney Disease: Improving Global Outcomes (KDIGO) classification when available. Follow-up assessments include discharge and postoperative days 30 and 90 and months 6 and 12.

The study targets 50 consecutive participants based on expected accrual over up to 5 years. Event rates will be presented as counts and percentages with 95% confidence intervals. At an observed rate of 20% (10 of 50), the Wilson 95% confidence interval would be approximately 11% to 33%. Changes in serum creatinine and estimated glomerular filtration rate will be summarized from baseline. Subgroup and longitudinal analyses will be exploratory.

The investigators will maintain a screening log and collect data in a coded electronic case report form with a data dictionary and prespecified time windows. Range, consistency and missing-data checks will be completed before database lock. Two investigators will review acute kidney injury stage, major adverse kidney events and serious technique-related events when feasible. Available denominators will be reported for each outcome. The primary outcome will use observed data, with a creatinine-only analysis when urine-output records are incomplete.

Study Type

Observational

Enrollment (Estimated)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Adults undergoing open abdominal aortic reconstruction with suprarenal or supravisceral cross-clamping at Policlinico di Sant'Orsola in Bologna, Italy, for whom the surgical team selects temporary renal blood perfusion.

Description

Inclusion Criteria:

  1. Age 18 years or older.

  2. Open abdominal aortic reconstruction requiring suprarenal or supravisceral cross-clamping.

  3. Independent clinical decision by the treating surgeon to use the described renal perfusion circuit.

  4. At least one renal artery intended for shunt perfusion.

  5. Written informed consent before surgery through the approved process.

    Exclusion Criteria:

  6. Maintenance kidney replacement therapy before surgery.

  7. No initiation of renal shunt perfusion after consent.

  8. Inability or unwillingness to provide informed consent under the approved process.

  9. Pregnancy.

  10. Primary renal perfusion using cardiopulmonary bypass or a dedicated visceral perfusion system.

  11. Clinical contraindication to brachial access or renal ostial cannulation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Postoperative acute kidney injury
Time Frame: End of surgery through postoperative day 7

Number and percentage of participants meeting KDIGO 2012 criteria. Acute kidney injury is defined by a serum creatinine rise of at least 0.3 mg/dL within 48 hours, serum creatinine at least 1.5 times the reference within 7 days, or urine output below 0.5 mL/kg/hour for at least 6 hours. Reference creatinine is the most recent stable value 7 to 90 days before surgery, or the preoperative value if a stable historical value is unavailable. Cases with preoperative acute kidney injury will be adjudicated and described separately.

End of surgery through postoperative day 7

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2026

Primary Completion (Estimated)

December 1, 2028

Study Completion (Estimated)

December 1, 2031

Study Registration Dates

First Submitted

November 15, 2026

First Submitted That Met QC Criteria

November 15, 2026

First Posted (Actual)

November 20, 2026

Study Record Updates

Last Update Posted (Actual)

November 20, 2026

Last Update Submitted That Met QC Criteria

November 15, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe